The narcolepsy treatment market is witnessing substantial growth due to the increasing prevalence of narcolepsy and advancements in treatment options. Emerging treatments, such as orexin receptor antagonists, are enhancing therapeutic approaches by targeting underlying pathways in narcolepsy pathophysiology. Recently, companies such as Avadel and Jazz Pharmaceuticals have gained attention with innovative drugs showing promising results in managing narcolepsy symptoms more effectively. The market's expansion is also supported by increased awareness of sleep disorders and better diagnosis rates. Growth is projected to continue as R&D in neurotherapeutics and advancements in telemedicine improve diagnosis and access to care, benefiting patients and supporting market dynamics.
